Mesa Laboratories SVP Brian Archbold Buys Shares of MLAB

Mesa Laboratories, Inc. (NasdaqGS: MLAB) saw insider buying activity from Brian Archbold, the company's Senior Vice President of Operations. On June 18, 2026, Archbold purchased 3,324 shares at an average price of $95.10 each, amounting to a total value of $316,112.40. This transaction was not part of a pre-planned trading program.

Other Institutional Activity in Mesa Laboratories

Long Path Partners significantly increased its stake in Mesa Laboratories, adding 178,360 shares, bringing its total holdings to 405,583 shares, valued at approximately $35.9 million. BlackRock, Inc. slightly reduced its position by 4,815 shares, maintaining 393,851 shares worth about $34.8 million. Boston Partners also expanded its investment, adding 55,335 shares to hold a total of 268,711 shares, valued at $23.8 million. Select Equity Group, L.P. increased its stake by 29,450 shares, reaching 235,885 shares valued at $20.9 million. Meanwhile, Vanguard Capital Management LLC initiated a new position with 232,643 shares, valued at $20.6 million.

Mesa Laboratories, Inc. Stock Down 27.7%

On Tuesday, shares of Mesa Laboratories, Inc. traded near $93.23. The company, which operates in the scientific and technical instruments sector, has a market capitalization of $515 million. Its stock has a P/E ratio of 77.0 and a forward P/E of 7.6, with a beta of 0.927. Over the past 52 weeks, the stock has ranged from a low of $55.45 to a high of $113.99. The 50-day moving average is $101.99, and the 200-day moving average is $84.97.

Insider Buying and Selling at Mesa Laboratories, Inc.

In addition to Brian Archbold's purchase, CFO John Sakys also acquired 2,282 shares on June 18, 2026, at the same price of $95.10. On June 22, 2026, several insiders, including Archbold and CAO Lyndsey Elizabeth Crennen, sold shares at a price of $89.50, with Crennen selling 442 shares and Archbold 2,516 shares.

Analysts Set New Price Targets

Analysts have set new price targets for Mesa Laboratories. On February 4, 2026, Wells Fargo maintained its hold rating with a target price of $94.00. Evercore ISI has consistently maintained a buy rating, with its most recent target set at $106.00. Overall, the consensus among analysts is a hold rating, with a mean target price of $112.00.

About Mesa Laboratories

Mesa Laboratories, Inc., headquartered in Lakewood, Colorado, designs and manufactures life sciences tools and quality control products. The company operates in several segments, including Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions. Founded in 1982, Mesa Labs provides solutions for industries such as healthcare, pharmaceuticals, and scientific research.

Bottom Line

Brian Archbold's recent purchase of Mesa Laboratories shares highlights insider confidence in the company. Investors often watch insider transactions as potential indicators of a company's prospects. However, it's essential to remember that insider buying is only one piece of the puzzle, and these transactions are reported after the fact. As always, investors should consider a range of factors when evaluating stock opportunities.